| Bioactivity | GZR18 is an analog of glucagon-like peptide-1 (GLP-1), which exhibits agonistic activity for GLP-1 receptor, with an EC50 of 0.677 nM. GZR18 ameliorates type 2 diabetes[1]. |
| Target | EC50: 0.677 nM (GLP-1 Receptor) |
| Invitro | GZR18 (30-90 nM，0.5-1 h) 剂量依赖性地刺激小鼠胰岛 β 细胞的葡萄糖依赖性胰岛素分泌[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> GZR18 相关抗体: |
| In Vivo | GZR18 (0-100 nmol/kg，皮下注射，单剂量或 11 次注射) 在 db/db 小鼠糖尿病模型中降低小鼠的血糖水平，减轻小鼠体重，具有控制血糖的作用[1]。GZR18 (60 μg/kg，静脉注射或皮下注射，单剂量) 在食蟹猴模型中展现出良好的药代动力学特性[1]。GZR18 在食蟹猴模型中的药代动力学特征[1]route |
| Sequence | His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Ala-Glu-Glu-Ala-Ala-Glu-Glu-Ala-gammaGlu-C22 diacid)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly |
| Shortening | HGEGTFTSDVSSYLEGQAA-K(AEEA-AEEA-gammaGlu-C22 diacid)-EFIAWLVRGRG |
| Formula | C189H295N45O59 |
| Molar Mass | 4141.63 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhang M, et al., GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models. Eur J Pharmacol. 2022 Aug 5;928:175107. |